Influence of molecular size on tissue distribution of antibody fragments

mAbs

Volumn 8, Issue 1, 2016, Pages 113-119

  Li, Zhe ^a   Krippendorff, Ben Fillippo ^b   Sharma, Sharad ^a   Walz, Antje C ^b   Lavé, Thierry ^b   Shah, Dhaval K ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Antibody Fragments; Biodistribution Coefficient (BC); Biologics; Monoclonal Antibody (mAb); PBPK Model; QSPKR; Tissue Distribution

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; IMMUNOGLOBULIN FRAGMENT;

ARTICLE; BIODISTRIBUTION COEFFICIENT; CONSTANTS AND COEFFICIENTS; MOLECULAR WEIGHT; PROTEIN LOCALIZATION; PROTEIN SIZE; PROTEIN STRUCTURE, FUNCTION AND VARIABILITY; ANIMAL; BIOLOGICAL MODEL; HUMAN; TISSUE DISTRIBUTION;

ANIMALS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MODELS, BIOLOGICAL; MOLECULAR WEIGHT; TISSUE DISTRIBUTION;

EID: 84964478816     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1111497     Document Type: Article

References (16)

1. Shah DK, Betts AM. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. mAbs 2013; 5:297-305; PMID:23406896; http://dx.doi.org/10.4161/mabs.23684.
2. Rippe B, Haraldsson B. Transport of macromolecules across microvascular walls: the two-pore theory. Physiol Rev 1994; 74:163-219; PMID:8295933
3. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55:3752-6; PMID:7641188
4. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 2007; 109:170-9; PMID:17154393; http://dx.doi.org/10.1002/cncr.22402
5. Vegt E, de Jong M, Wetzels JF, Masereeuw R, Melis M, Oyen WJ, Gotthardt M, Boerman OC. Renal toxicity of radiolabeled peptides and antibody fragments:mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 2010; 51:1049-58; PMID:20554737; http://dx.doi.org/10.2967/jnumed.110.075101
6. Hong H, Zhang Y, Orbay H, Valdovinos HF, Nayak TR, Bean J, Theuer CP, Barnhart TE, Cai W. Positron emission tomography imaging of tumor angiogenesis with a (61/64)Cu-labeled F(ab')(2) antibody fragment. Mol Pharm 2013; 10:709-16; PMID:23316869; http://dx.doi.org/10.1021/mp300507r
7. Sandstrom K, Haylock AK, Spiegelberg D, Qvarnstrom F, Wester K, Nestor M. A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio. Int J Oncol 2012; 40:1525-32; PMID:22307465
8. Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenesis Res 2010; 2:14; PMID:20701757; http://dx.doi.org/10.1186/2040-2384-2-14
9. Cooper PR, Ciambrone GJ, Kliwinski CM, Maze E, Johnson L, Li Q, Feng Y, Hornby PJ. Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn. Brain Res 2013; 1534:13-21; PMID:23978455; http://dx.doi.org/10.1016/j. brainres.2013.08.035
10. Schlachetzki F, Zhu C, Pardridge WM. Expression of the neonatal Fc receptor (FcRn) at the bloodbrain barrier. J Neurochem 2002; 81:203-6; PMID:12067234; http://dx.doi.org/10.1046/j.1471-4159.2002.00840.x
11. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009; 8:2861-71; PMID:19825804; http://dx.doi.org/10.1158/1535-7163.MCT-09-0195
12. Boswell CA, Mundo EE, Ulufatu S, Bumbaca D, Cahaya HS, Majidy N, Van Hoy M, Schweiger MG, Fielder PJ, Prabhu S, et al. Comparative physiology of mice and rats: radiometric measurement of vascular parameters in rodent tissues. Mol Pharm 2014; 11:1591-8; PMID:24702191; http://dx.doi.org/10.1021/mp400748t
13. Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 2012; 39:67-86; PMID:22143261; http://dx.doi.org/10.1007/s10928-011-9232-2
14. Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 2007; 34:687-709; PMID:17636457; http://dx.doi.org/10.1007/s10928-007-9065-1
15. Chen N, Wang W, Fauty S, Fang Y, Hamuro L, Hussain A, Prueksaritanont T. The effect of the neonatal Fc receptor on human IgG biodistribution in mice. mAbs 2014; 6:502-8; PMID:24492305; http://dx.doi.org/10.4161/mabs.27765
16. Venturoli D, Rippe B. Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. Am J Physiol Renal Physiol 2005; 288:F605-13; PMID:15753324; http://dx.doi.org/10.1152/ajprenal.00171.2004